{"id":"NCT01911780","sponsor":"Boehringer Ingelheim","briefTitle":"Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine","officialTitle":"An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg, Followed by a 52 Weeks Extension Study to Assess Long Term Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07","primaryCompletion":"2015-01","completion":"2015-01","firstPosted":"2013-07-30","resultsPosted":"2016-03-28","lastUpdate":"2016-03-28"},"enrollment":132,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"telmisartan + HCTZ","otherNames":[]},{"type":"DRUG","name":"telmisartan + HCTZ","otherNames":[]},{"type":"DRUG","name":"amlodipine","otherNames":[]}],"arms":[{"label":"telmisartan + HCTZ + amlodipine","type":"EXPERIMENTAL"},{"label":"telmisartan + HCTZ + placebo","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multi-centre, randomised, double-blind, active-controlled, parallel-group comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg + hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5 mg) to telmisartan 80 mg+ hydrochlorothiazide 12.5 mg (T80/H12.5 mg) in blood pressure lowering effect at week 8, the end of the double-blind period in essential hypertensive patients who fail to respond adequately to telmisartan 80 mg+ hydrochlorothiazide 12.5 mg.\n\nPatients are assigned to one of the two groups after a 6-week open-label run-in period taking T80/H12.5 mg.\n\nIn addition the long-term safety of telmisartan 80 mg+ amlodipine 5 mg+ hydrochlorothiazide 12.5 mg will be evaluated in a 52-week extension period.\n\nIn the 52-week open label extension period patients who are assigned to the T80/A5/H12.5 mg group continue the T80/A5/H12.5 mg therapy, and patients who are assigned to the T80/ /H12.5 mg group change to the T80/A5/H12.5 mg therapy.","primaryOutcome":{"measure":"Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.","timeFrame":"baseline and 8 weeks","effectByArm":[{"arm":"Telmisartan + HCTZ + Amlodipine","deltaMin":-8.8,"sd":0.8},{"arm":"Telmisartan + HCTZ + Placebo","deltaMin":-1.3,"sd":0.8}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":68},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation"]}}